Two Onc Docs cover image

ASH 2025 LBA BRUIN-CLL 313 Update: Pirtobrutinib vs Bendamustine/Rituximab in 1L CLL

Two Onc Docs

00:00

Safety profile of pirtobrutinib

Kareen reviews key toxicities: bleeding, arthralgias, hypertension, and low atrial fibrillation rates.

Play episode from 06:43
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app